Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles facing drug innovation under the new reimbursement system, as well as the steps that must be taken to bolster the Austrian innovation sector and attract international companies to establish themselves firmly in Austria. He also gives an overview of the digital revolution and the path Austria must take to consider itself a world innovation hub.
As president, could you introduce the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI) to our international readers?
"We are facilitating a crucial step in a drug development cycle, so that patients in Austria can receive innovative treatment as early as possible."
